Norvancomycin | CAS#198774-23-1 | Glycopeptide antibiotic

MedKoo Cat#: 465308 | Name: Norvancomycin

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Norvancomycin is a glycopeptide antibiotic that has been found in Nocardia orientalis. It is active against several strains of S. aureus and S. epidermidis in vitro and in vivo. Formulations containing Norvancomycin have been used in the treatment of bacterial infections.

Chemical Structure

Norvancomycin

CAS#198774-23-1

Theoretical Analysis

MedKoo Cat#: 465308

Name: Norvancomycin

CAS#: 198774-23-1

Chemical Formula: C64H72Cl3N9O24

Exact Mass:

Molecular Weight: 1457.67

Elemental Analysis: C, 52.74; H, 4.98; Cl, 7.30; N, 8.65; O, 26.34

Price and Availability

Size	Price	Availability
5mg	USD 230.00	2 Weeks
10mg	USD 380.00	2 Weeks
25mg	USD 650.00	2 Weeks
50mg	USD 990.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

Norvancomycin; A51568A; A 51568A; A-51568A; N-Demethylvancomycin HCl; N Demethylvancomycinb HCl; N-Demethylvancomycin hydrochloride; N Demethylvancomycin hydrochloride;

IUPAC/Chemical Name

N/A

InChi Key

KIWZUNMYMZEVBK-PJWQOMLFSA-N

InChi Code

InChI=1S/C64H71Cl2N9O24.ClH/c1-4-5-32(67)56(86)74-47-49(81)24-7-10-36(30(65)13-24)95-38-15-26-16-39(53(38)99-63-54(52(84)51(83)40(21-76)97-63)98-42-20-64(3,69)55(85)22(2)94-42)96-37-11-8-25(14-31(37)66)50(82)48-61(91)73-46(62(92)93)29-17-27(77)18-35(79)43(29)28-12-23(6-9-34(28)78)44(58(88)75-48)72-59(89)45(26)71-57(87)33(19-41(68)80)70-60(47)90;/h6-18,22,32-33,40,42,44-52,54-55,63,76-79,81-85H,4-5,19-21,67,69H2,1-3H3,(H2,68,80)(H,70,90)(H,71,87)(H,72,89)(H,73,91)(H,74,86)(H,75,88)(H,92,93);1H/t22-,32+,33-,40+,42-,44+,45+,46-,47+,48-,49+,50+,51+,52-,54+,55+,63-,64-;/m0./s1

SMILES Code

ClC1=CC([C@@H](O)[C@@H](NC([C@@H](CCC)N)=O)C(N[C@@H](CC(N)=O)C(N[C@@](C(N[C@@]([H])(C2=O)C3=CC=C(C4=C3)O)=O)5[H])=O)=O)=CC=C1OC6=C(O[C@H]7[C@H](O[C@H]8C[C@]([C@H](O)[C@H](C)O8)(C)N)[C@@H](O)[C@H](O)[C@@H](CO)O7)C(OC9=CC=C([C@H]([C@@](C(N[C@@H](C%10=CC(O)=CC(O)=C%104)C(O)=O)=O)(N2)[H])O)C=C9Cl)=CC5=C6.Cl

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

To be determined

Shelf Life

>2 years if stored properly

Drug Formulation

To be determined

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

	Solvent	mg/mL	mM
Solubility
	PBS (pH 7.2)	1.0	0.69
	Ethanol	10.0	6.86

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 1,457.67 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Lin W, Zhao L, Tan Q, Lin D. Treatment of Severe Acute Bacterial Keratitis in Rabbits Using Continuous Topical Ocular Instillation with Norvancomycin. Drug Des Devel Ther. 2021 Feb 16;15:617-628. doi: 10.2147/DDDT.S295874. PMID: 33623371; PMCID: PMC7896742. 2: Li X, Zhang C, Zhao Y, Lei X, Jiang Z, Zhang X, Zheng Z, Si S, Wang L, Hong B. Comparative genomics and transcriptomics analyses provide insights into the high yield and regulatory mechanism of Norvancomycin biosynthesis in Amycolatopsis orientalis NCPC 2-48. Microb Cell Fact. 2021 Feb 2;20(1):28. doi: 10.1186/s12934-021-01521-6. PMID: 33531006; PMCID: PMC7852140. 3: Shen Q, Zhu X, Zhao Q, Li S, Wang Y, Xue J, Wang P. QuEChERS and 96-well plate solid phase extraction for determination of vancomycin and norvancomycin in fish meat by UPLC-MS/MS. Food Chem. 2021 Apr 16;342:128326. doi: 10.1016/j.foodchem.2020.128326. Epub 2020 Oct 10. PMID: 33069533. 4: Yang Q, Li X, Jia P, Giske C, Kahlmeter G, Turnidge J, Yu Y, Lv Y, Wang M, Sun Z, Lin J, Li Y, Zheng B, Hu F, Guo Y, Chen Z, Li H, Zhang G, Zhang J, Kang W, Duan S, Wang T, Jing R, Xu Y; Chinese Committee on Antimicrobial Susceptibility Testing (ChiCAST). Determination of norvancomycin epidemiological cut-off values (ECOFFs) for Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus haemolyticus and Staphylococcus hominis. J Antimicrob Chemother. 2021 Jan 1;76(1):152-159. doi: 10.1093/jac/dkaa414. PMID: 33057728. 5: Fan Y, Peng X, Wu H, Liang X, Chen Y, Guo B, Zhang J. Simultaneous separation and determination of vancomycin and its crystalline degradation products in human serum by ultra high performance liquid chromatography tandem mass spectrometry method and its application in therapeutic drug monitoring. J Sep Sci. 2020 Nov;43(21):3987-3994. doi: 10.1002/jssc.202000691. Epub 2020 Oct 7. PMID: 32845063. 6: Wang J, Li SC, Ye Q, Gao LL, Nie YM, Xu H, Wu M, Cao P, Wang Y. Population Pharmacokinetics and Pharmacodynamics of Norvancomycin in Children With Malignant Hematological Disease. J Clin Pharmacol. 2020 Sep;60(9):1220-1230. doi: 10.1002/jcph.1618. Epub 2020 Jun 2. PMID: 32488878. 7: Zhou YL, Wang YX, Yao TT, Yang Y, Wang ZY. Traumatic endophthalmitis and the outcome after vitrectomy in young children. Int J Ophthalmol. 2020 Mar 18;13(3):406-411. doi: 10.18240/ijo.2020.03.06. PMID: 32309176; PMCID: PMC7154189. 8: Lin W, Zhao L, Huang X, Tan Q, Peng M, Khan MA, Lin D. Comparative Assessment of Distribution Characteristics and Ocular Pharmacokinetics of Norvancomycin Between Continuous Topical Ocular Instillation and Hourly Administration of Eye Drop. Drug Des Devel Ther. 2020 Feb 26;14:867-879. doi: 10.2147/DDDT.S233047. PMID: 32161446; PMCID: PMC7049745. 9: Qiu X, Wu Y, Jiang Y, Ji Y, Zhu X, Yang J, Lu Y. Management and Microbiological Characteristics of Membrane Formation on a Hydrophilic Acrylic Intraocular Lens: A Clinical Case Series and Material Comparative Study of Different IOLs. J Ophthalmol. 2019 Feb 3;2019:5746186. doi: 10.1155/2019/5746186. PMID: 30863625; PMCID: PMC6377987. 10: Liu M, Yang ZH, Li GH. A Novel Method for the Determination of Vancomycin in Serum by High-Performance Liquid Chromatography-Tandem Mass Spectrometry and Its Application in Patients with Diabetic Foot Infections. Molecules. 2018 Nov 10;23(11):2939. doi: 10.3390/molecules23112939. PMID: 30423820; PMCID: PMC6278353. 11: Zhu LL, Zhou Q. Optimal infusion rate in antimicrobial therapy explosion of evidence in the last five years. Infect Drug Resist. 2018 Aug 8;11:1105-1117. doi: 10.2147/IDR.S167616. PMID: 30127628; PMCID: PMC6089111. 12: Li X, Wu Y, Sun S, Wang Q, Zhao Z. Factors Influencing Norvancomycin Concentration in Plasma and Cerebrospinal Fluid in Patients After Craniotomy and Dosing Guideline: A Population Approach. Clin Ther. 2018 Jan;40(1):74-82.e1. doi: 10.1016/j.clinthera.2017.11.005. Epub 2017 Dec 8. PMID: 29229228. 13: Mei S, Wang J, Cheng Q, Zhu L, Yang L, Chen R, Zhao Z. Development, validation, and application of an UPLC-MS/MS method for norvancomycin analysis in human blood plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2018 Jan 1;1072:199-204. doi: 10.1016/j.jchromb.2017.11.024. Epub 2017 Nov 21. PMID: 29179060. 14: Li J, He S, Yang Z, Lu C. Pharmacokinetics and cerebrospinal fluid penetration of norvancomycin in Chinese adult patients. Int J Antimicrob Agents. 2017 May;49(5):603-608. doi: 10.1016/j.ijantimicag.2017.01.014. Epub 2017 Mar 30. PMID: 28366660. 15: Lei X, Zhang C, Jiang Z, Li X, Shi Y, Liu M, Xie Y, Wang L, Hong B. Complete genome sequence of Amycolatopsis orientalis CPCC200066, the producer of norvancomycin. J Biotechnol. 2017 Apr 10;247:6-10. doi: 10.1016/j.jbiotec.2017.02.013. Epub 2017 Feb 16. PMID: 28216102. 16: Yang H, Hao Y, Liu Q, Mi Z, Wang Z, Zhu L, Feng Q, Hu N. Preparation and in vitro study of hydrochloric norvancomycin encapsulated poly (d,l-lactide-co- glycolide, PLGA) microspheres for potential use in osteomyelitis. Artif Cells Nanomed Biotechnol. 2017 Nov;45(7):1326-1330. doi: 10.1080/21691401.2016.1233110. Epub 2016 Oct 24. PMID: 27776425. 17: Wu Y, Kang J, Wang Q. Drug concentrations in the serum and cerebrospinal fluid of patients treated with norvancomycin after craniotomy. Eur J Clin Microbiol Infect Dis. 2017 Feb;36(2):305-311. doi: 10.1007/s10096-016-2803-9. Epub 2016 Oct 13. PMID: 27738856; PMCID: PMC5253146. 18: Jiang Z, Lei X, Chen M, Jiang B, Wu L, Zhang X, Zheng Z, Hu X, You X, Si S, Wang L, Hong B. Three structurally-related impurities in norvancomycin drug substance. J Antibiot (Tokyo). 2017 Feb;70(2):158-165. doi: 10.1038/ja.2016.115. Epub 2016 Oct 5. PMID: 27703158. 19: Wu H, Ding X, Zhang M, Xu G. Pediatric posttraumatic endophthalmitis. Graefes Arch Clin Exp Ophthalmol. 2016 Oct;254(10):1919-1922. doi: 10.1007/s00417-016-3330-1. Epub 2016 Apr 12. PMID: 27067874. 20: Yan J, Guo Z, Ding J, Shen A, Wang J, Jin G, Liang X. [Analysis of vancomycin and its related impurities by hydrophilic interaction liquid chromatography]. Se Pu. 2015 Sep;33(9):951-6. Chinese. doi: 10.3724/sp.j.1123.2015.05032. PMID: 26753283.